Prestige Consumer Healthcare Inc (PBH)

In May 2025, Prestige Consumer Healthcare reported record fiscal year revenue and earnings, exceeding expectations due to international business performance and e-commerce success. In August 2025, the company's first-quarter fiscal earnings fell short of analyst expectations, leading to adjusted ratings and price targets from analysts like Canaccord Genuity Group and Wall Street Zen. In September 2025, Zacks Research downgraded shares to a "strong sell" rating, and the stock reached a new 52-week low. Later in September, Sidoti upgraded shares to a "buy" rating. In October 2025, Weiss Ratings reiterated a "hold" rating, Oppenheimer lowered its price target, and Jefferies Financial Group reduced its price objective. Unforeseen production delays in the Clear Eyes product line have impacted revenue forecasts for Q1 fiscal 2026 and contributed to anticipated eye care supply constraints.

Demand for Prestige Consumer Healthcare's overall product portfolio generally remains stable, but some product categories exhibit seasonality. The company's Q2 fiscal year 2025 results were influenced by seasonal cough and cold ordering patterns. Global events, such as the COVID-19 pandemic, have historically boosted demand for OTC healthcare products. The company has also noted good sales growth in eye and ear care and dermatological products.

Prestige Consumer Healthcare Inc. specializes in marketing and distributing over-the-counter healthcare and household cleaning products, focusing on brand acquisition, product innovation, and revenue generation through retail channels and e-commerce. Its product portfolio includes pain relief medications like BC® Powder and Goody's® Powder, women's health products such as Monistat® and Summer's Eve®, eye care solutions like Clear Eyes® and TheraTears®, Dramamine® for motion sickness, DenTek® for oral care, Compound W® for wart treatment, Chloraseptic® and Luden's® for sore throat relief, digestive health products like Beano® and Fleet® enemas, and other products like Boudreaux's Butt Paste®, Nix®, Debrox®, and Hydralyte®.

Prestige Consumer Healthcare, Inc. distributes and sells its products primarily in North America, Australia, and certain other international markets. The company's headquarters are located in Tarrytown, New York, and it operates a manufacturing facility in Lynchburg, Virginia.

Prestige Consumer Healthcare has a reputation for owning trusted brands. The company has invested in brand building and marketing for key products like Hydralyte and Summer's Eve, which has contributed to enhancing consumer awareness and driving revenue growth.

Prestige Consumer Healthcare Inc. is primarily owned by institutional shareholders, who hold approximately 105.29% of the company's stock, and insiders, holding about 46.69%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Dimensional Fund Advisors LP. The largest individual shareholder is David Donnini, who owns 10.04 million shares, representing 20.31% of the company.